Overall rank by patents
#21,689
of 50,000 tracked assignees
USPTO PatentsView assignee record - 13 granted patents across 4 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
The verdict
According to USPTO PatentsView, Reviva ranks #21,689 of 50,000 tracked US assignees by granted-patent volume, with 13 patents across 4 technology areas.
USPTO PatentsView assignee plate
Corpus R21689 · US Corporation #21,689 · 13 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL
Nearest grant-volume peer: Reishauer Ag (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Reviva Pharmaceuticals · this assignee
31 score
3D Lighting Innovati… · lowest
7 score
What this shows Reviva's Innovation Score is 31.4/100 (top 62% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Reviva Pharmaceuticals, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). Peak complete grant year is 2016 (4 grants) versus a trough of 1 in 2019. By volume, Reviva sits between Reishauer Ag and Rhodia Poliamida E Especialidades S.a..
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
REISHAUER AG
13 patents
RENISHAW (IRELAND) LIMITED
13 patents
REPRIEVE CARDIOVASCULAR, INC.
13 patents
RESTEK CORPORATION
13 patents
REVIVO MEDICAL, LLC
13 patents
REYCO GRANNING, LLC
13 patents
RF360 Europe GmbH
13 patents
RHODIA POLIAMIDA E ESPECIALIDADES S.A.
13 patents
REVIVA PHARMACEUTICALS, INC.
13 patents
What this shows Reviva holds 13 patents at rank #21,667, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #21,667 in granted patent volume.
Other assignees with the most granted patents in Reviva's primary technology class.
Reviva's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
31 Top 62% higher than 38% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 2 | 15.4% |
| 2016 | 4 | 30.8% |
| 2017 | 2 | 15.4% |
| 2018 | 3 | 23.1% |
| 2019 | 1 | 7.7% |
| 2024 | 1 | 7.7% |
Top 4 of 4 technology areas
Overall rank by patents
#21,689
of 50,000 tracked assignees
31.4 out of 100
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.